By Ahmed Aboulenein and Maggie Fick WASHINGTON (Reuters) -AstraZeneca plans to spend $50 billion to expand manufacturing and ...

British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence ...

AstraZeneca's efforts are paying off as strong U.S. demand, and robust sales of newer cancer, heart and kidney disease ...

The U.K.-based drugmaker plans to invest $50 billion in the United States as the industry seeks to appease President Trump.

AstraZeneca has announced $50bn investment plans in the US by 2030 for drug manufacturing, and research and development (R&D) ...

With the threat of tariffs looming for medicines imported to the United States, AstraZeneca has unveiled a plan to invest $50 ...

British-Swedish pharmaceutical company AstraZeneca announced a $50 billion investment in the U.S. this week, with the Trump ...

President Donald Trump referenced the announcement the following day in Oval Office remarks, framing AstraZeneca’s overall ...

AstraZeneca, the U.K.-Swedish pharmaceutical giant, on Tuesday announced a plan to invest some $50 billion in the U.S. in a ...

The $50 billion target, which AstraZeneca plans to meet by 2030, includes new manufacturing projects in Virginia and ...

U.K.-based drug giant AstraZeneca will make what it calls its single-largest manufacturing investment in the world with a new ...

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...